BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28181257)

  • 1. Limited synchronous hepatic resection does not compromise peri-operative outcomes or survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Saxena A; Valle SJ; Liauw W; Morris DL
    J Surg Oncol; 2017 Mar; 115(4):417-424. PubMed ID: 28181257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
    Teo MC; Tan GH; Tham CK; Lim C; Soo KC
    Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Lyon TD; Turner Ii RM; Nikonow TN; Wang L; Uy J; Ramalingam L; Holtzman MP; Pingpank JF; Bartlett DL; Davies BJ
    J Surg Oncol; 2016 Feb; 113(2):218-22. PubMed ID: 26775909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogenic Blood Transfusion Is an Independent Predictor of Poorer Peri-operative Outcomes and Reduced Long-Term Survival after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Review of 936 Cases.
    Saxena A; Valle SJ; Liauw W; Morris DL
    J Gastrointest Surg; 2017 Aug; 21(8):1318-1327. PubMed ID: 28560703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes following synchronous liver resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases: A bi-institutional study.
    Flood MP; Waters PS; Kelly ME; Shields C; Conneely J; Ramsay R; Michael M; Loveday B; Warrier SK; Mulsow J; Heriot AG
    Surg Oncol; 2021 Jun; 37():101553. PubMed ID: 33839444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
    Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
    Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
    Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
    Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.
    Schneider MA; Eshmuminov D; Lehmann K
    Ann Surg Oncol; 2017 Aug; 24(8):2224-2232. PubMed ID: 28265776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
    Horvath P; Beckert S; Königsrainer A; Nadalin S; Königsrainer I
    J Visc Surg; 2019 Dec; 156(6):475-484. PubMed ID: 31324533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Randle RW; Doud AN; Levine EA; Clark CJ; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2015 May; 22(5):1634-8. PubMed ID: 25120252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC.
    Lee RM; Gamboa AC; Turgeon MK; Zaidi MY; Kimbrough C; Leiting J; Grotz T; Lee AJ; Fournier K; Powers B; Dineen S; Baumgartner JM; Veerapong J; Mogal H; Clarke C; Wilson G; Patel S; Hendrix R; Lambert L; Pokrzywa C; Abbott DE; LaRocca CJ; Raoof M; Greer J; Johnston FM; Staley CA; Cloyd JM; Maithel SK; Russell MC
    J Surg Oncol; 2021 Jan; 123(1):187-195. PubMed ID: 33002202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Survival and Propensity Score Matched Outcomes of Bilateral
    Singh B; Singh G; Pourgholami M; Alzahrani N; Morris DL
    Anticancer Res; 2018 Oct; 38(10):5917-5921. PubMed ID: 30275219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
    Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
    Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Patients with High-Grade, High-Volume Disseminated Mucinous Appendiceal Neoplasms.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2016 Feb; 23(2):382-90. PubMed ID: 26429720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases.
    Kyang LS; Alzahrani NA; Valle SJ; Rahman MK; Arrowaili A; Liauw W; Morris DL
    J Surg Oncol; 2019 Sep; 120(4):794-802. PubMed ID: 31309588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.